ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PRME vs GLUE // EV/EBITDA & P/E VALUATION

Prime Medicine Inc. (NASDAQ) VS. Monte Rosa Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PRME 2 — GLUE 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRME VS. GLUE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PRME GLUE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -17.58% -2.97% -14.61 GLUE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 55.30% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 61.5 44.6 +16.89 PRME /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $950.4M $927.4M $23.1M PRME /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PRME REV GLUE REV PRME GROSS % GLUE GROSS % PRME FCF GLUE FCF
FY 2025 $4.6M $0 — — -$167.1M -$27.5M
FY 2024 $3.0M $0 — — -$130.2M $38.0M
FY 2023 $0 $0 — — -$165.4M -$43.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRME // BETA —
GLUE // BETA —